500 mg [14C]-LX1606
LX1606.1-104-NRM
Phase 1 small_molecule completed
Quick answer
500 mg [14C]-LX1606 for Carcinoid Syndrome is a Phase 1 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LEXICON PHARMACEUTICALS, INC.
- Indication
- Carcinoid Syndrome
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed